Use of ivermectin in the treatment of COVID-19 in humans: integrative review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/20835 |
Resumo: | With the appearance of the first cases of infection by SARS-CoV-2, the WHO quickly declared a pandemic against COVID-19, due to the high speed and transmissibility of the disease. In this scenario, in addition to research for the development of new drugs and vaccines, existing and approved drugs have also been studied, through the repositioning of drugs, as an alternative for the treatment of COVID-19, as is the case with ivermectin. Since then, several clinical trials have been carried out around the world to evaluate the antiviral action of ivermectin against COVID-19. Thus, this integrative review aims to analyze the scientific literature dealing with clinical trials on the use of ivermectin as a treatment for COVID-19, describing the works, as well as discussing their results and limitations. The search for scientific studies published in electronic databases: PubMed, LILACS and SciELO was carried out, using the keywords “IVERMECTIN and COVID-19” and “IVERMECTIN and SARS-COV-2”. Articles published from 2019 onwards, which worked on the use of ivermectin as a treatment for COVID-19, were selected. The research found studies that showed both positive and negative results for the use of ivermectin in relation to some parameters of the treatment of COVID-19. However, the works in general have methodological limitations. Thus, current evidence on the use of this drug to treat patients with COVID-19 is inconclusive, indicating the need for further well-designed and structured clinical trials to confirm or rule out these findings. |
id |
UNIFEI_821f06b3e9a9885332b05c4638422df0 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/20835 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Use of ivermectin in the treatment of COVID-19 in humans: integrative reviewUso de ivermectina en el tratamiento de COVID-19 en humanos: revisión integrativa Uso da ivermectina no tratamento da COVID-19 em humanos: revisão integrativa IvermectinCOVID-19TreatmentClinical studies.IvermectinaCOVID-19TratamientoEstudios clínicos.IvermectinaCOVID-19TratamentoEstudos clínicos.With the appearance of the first cases of infection by SARS-CoV-2, the WHO quickly declared a pandemic against COVID-19, due to the high speed and transmissibility of the disease. In this scenario, in addition to research for the development of new drugs and vaccines, existing and approved drugs have also been studied, through the repositioning of drugs, as an alternative for the treatment of COVID-19, as is the case with ivermectin. Since then, several clinical trials have been carried out around the world to evaluate the antiviral action of ivermectin against COVID-19. Thus, this integrative review aims to analyze the scientific literature dealing with clinical trials on the use of ivermectin as a treatment for COVID-19, describing the works, as well as discussing their results and limitations. The search for scientific studies published in electronic databases: PubMed, LILACS and SciELO was carried out, using the keywords “IVERMECTIN and COVID-19” and “IVERMECTIN and SARS-COV-2”. Articles published from 2019 onwards, which worked on the use of ivermectin as a treatment for COVID-19, were selected. The research found studies that showed both positive and negative results for the use of ivermectin in relation to some parameters of the treatment of COVID-19. However, the works in general have methodological limitations. Thus, current evidence on the use of this drug to treat patients with COVID-19 is inconclusive, indicating the need for further well-designed and structured clinical trials to confirm or rule out these findings.Con la aparición de los primeros casos de infección por SARS-CoV-2, la OMS rápidamente declaró una pandemia contra COVID-19, debido a la alta velocidad y transmisibilidad de la enfermedad. En este escenario, además de la investigación para el desarrollo de nuevos medicamentos y vacunas, también se estudiaron medicamentos existentes y aprobados, a través del reposicionamiento de medicamentos, como alternativa para el tratamiento del COVID-19, como es el caso de la ivermectina. Desde entonces, se han realizado varios ensayos clínicos en todo el mundo para evaluar la acción antiviral de la ivermectina contra COVID-19. Así, esta revisión integradora tiene como objetivo analizar la literatura científica que trata sobre ensayos clínicos sobre el uso de ivermectina como tratamiento para el COVID-19, describiendo los trabajos, así como discutiendo sus resultados y limitaciones. Se realizó la búsqueda de estudios científicos publicados en bases de datos electrónicas: PubMed, LILACS y SciELO, utilizando las palabras clave “IVERMECTIN y COVID-19” e “IVERMECTIN y SARS-COV-2”. Se seleccionaron los artículos publicados a partir de 2019 que trabajaban sobre el uso de ivermectina como tratamiento para COVID-19. La investigación encontró estudios que mostraron resultados tanto positivos como negativos para el uso de ivermectina en relación con algunos parámetros del tratamiento de COVID-19. Sin embargo, los trabajos en general tienen limitaciones metodológicas. Por lo tanto, la evidencia actual sobre el uso de este medicamento para tratar a pacientes con COVID-19 no es concluyente, lo que indica la necesidad de más ensayos clínicos bien diseñados y estructurados para confirmar o descartar estos hallazgos.Com o aparecimento dos primeiros casos de infecção pelo SARS-CoV-2, a OMS declarou rapidamente pandemia frente a COVID-19, devido à alta velocidade e transmissibilidade da doença. Nesse cenário, além das pesquisas para o desenvolvimento de novos fármacos e vacinas, passou-se também a estudar medicamentos já existentes e aprovados, através do reposicionamento de fármacos, como alternativa para o tratamento da COVID-19, como é o caso da ivermectina. Desde então, vários ensaios clínicos estão sendo realizados ao redor do mundo para avaliar a ação antiviral da ivermectina frente a COVID-19. Dessa forma, essa revisão integrativa tem por objetivo analisar a literatura científica que trata de ensaios clínicos sobre o uso da ivermectina como tratamento para a COVID-19, descrevendo os trabalhos, bem como, discutindo seus resultados e limitações. Procedeu-se a busca de estudos científicos publicados nas bases eletrônicas de dados: PubMed, LILACS e SciELO, utilizando as palavras chaves “IVERMECTIN and COVID-19” e “IVERMECTIN and SARS-COV-2”. Selecionou-se artigos publicados a partir de 2019, que trabalharam o emprego da ivermectina como tratamento para a COVID-19. A pesquisa encontrou estudos que demonstraram resultados tanto positivos quanto negativos para o uso da ivermectina frente alguns parâmetros do tratamento da COVID-19. Todavia, os trabalhos de forma geral, apresentam limitações metodológicas. Dessa forma, a evidência atual sobre o uso desse medicamento para tratar pacientes com COVID-19 é inconclusiva, indicando a necessidade de novos ensaios clínicos bem desenhados e estruturados, para confirmar ou descartar essas descobertas.Research, Society and Development2021-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2083510.33448/rsd-v10i12.20835Research, Society and Development; Vol. 10 No. 12; e564101220835Research, Society and Development; Vol. 10 Núm. 12; e564101220835Research, Society and Development; v. 10 n. 12; e5641012208352525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/20835/18557Copyright (c) 2021 Nicoli Maciel; Vivian Binder Neis ; Adrielli Tenfen https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMaciel, NicoliNeis , Vivian BinderTenfen , Adrielli2021-11-14T20:26:51Zoai:ojs.pkp.sfu.ca:article/20835Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:40:22.087627Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review Uso de ivermectina en el tratamiento de COVID-19 en humanos: revisión integrativa Uso da ivermectina no tratamento da COVID-19 em humanos: revisão integrativa |
title |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review |
spellingShingle |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review Maciel, Nicoli Ivermectin COVID-19 Treatment Clinical studies. Ivermectina COVID-19 Tratamiento Estudios clínicos. Ivermectina COVID-19 Tratamento Estudos clínicos. |
title_short |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review |
title_full |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review |
title_fullStr |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review |
title_full_unstemmed |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review |
title_sort |
Use of ivermectin in the treatment of COVID-19 in humans: integrative review |
author |
Maciel, Nicoli |
author_facet |
Maciel, Nicoli Neis , Vivian Binder Tenfen , Adrielli |
author_role |
author |
author2 |
Neis , Vivian Binder Tenfen , Adrielli |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Maciel, Nicoli Neis , Vivian Binder Tenfen , Adrielli |
dc.subject.por.fl_str_mv |
Ivermectin COVID-19 Treatment Clinical studies. Ivermectina COVID-19 Tratamiento Estudios clínicos. Ivermectina COVID-19 Tratamento Estudos clínicos. |
topic |
Ivermectin COVID-19 Treatment Clinical studies. Ivermectina COVID-19 Tratamiento Estudios clínicos. Ivermectina COVID-19 Tratamento Estudos clínicos. |
description |
With the appearance of the first cases of infection by SARS-CoV-2, the WHO quickly declared a pandemic against COVID-19, due to the high speed and transmissibility of the disease. In this scenario, in addition to research for the development of new drugs and vaccines, existing and approved drugs have also been studied, through the repositioning of drugs, as an alternative for the treatment of COVID-19, as is the case with ivermectin. Since then, several clinical trials have been carried out around the world to evaluate the antiviral action of ivermectin against COVID-19. Thus, this integrative review aims to analyze the scientific literature dealing with clinical trials on the use of ivermectin as a treatment for COVID-19, describing the works, as well as discussing their results and limitations. The search for scientific studies published in electronic databases: PubMed, LILACS and SciELO was carried out, using the keywords “IVERMECTIN and COVID-19” and “IVERMECTIN and SARS-COV-2”. Articles published from 2019 onwards, which worked on the use of ivermectin as a treatment for COVID-19, were selected. The research found studies that showed both positive and negative results for the use of ivermectin in relation to some parameters of the treatment of COVID-19. However, the works in general have methodological limitations. Thus, current evidence on the use of this drug to treat patients with COVID-19 is inconclusive, indicating the need for further well-designed and structured clinical trials to confirm or rule out these findings. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/20835 10.33448/rsd-v10i12.20835 |
url |
https://rsdjournal.org/index.php/rsd/article/view/20835 |
identifier_str_mv |
10.33448/rsd-v10i12.20835 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/20835/18557 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Nicoli Maciel; Vivian Binder Neis ; Adrielli Tenfen https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 Nicoli Maciel; Vivian Binder Neis ; Adrielli Tenfen https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 12; e564101220835 Research, Society and Development; Vol. 10 Núm. 12; e564101220835 Research, Society and Development; v. 10 n. 12; e564101220835 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052756510375936 |